Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer.

Goossens-Laan CA, Leliveld AM, Verhoeven RH, Kil PJ, de Bock GH, Hulshof MC, de Jong IJ, Coebergh JW.

Int J Cancer. 2014 Aug 15;135(4):905-12. doi: 10.1002/ijc.28716. Epub 2014 Jan 25.

PMID:
24420527
[PubMed - indexed for MEDLINE]
2.

Patient-reported outcomes for patients undergoing radical cystectomy: a prospective case-control study.

Goossens-Laan CA, Kil PJ, Bosch JL, De Vries J.

Support Care Cancer. 2014 Jan;22(1):189-200. doi: 10.1007/s00520-013-1946-9. Epub 2013 Sep 13.

PMID:
24026979
[PubMed - indexed for MEDLINE]
3.

Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.

van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ; NEPTUNE Study Group.

Eur Urol. 2013 Dec;64(6):1003-12. doi: 10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3.

PMID:
23932438
[PubMed - indexed for MEDLINE]
4.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
[PubMed - indexed for MEDLINE]
5.

Pre-diagnosis quality of life (QoL) in patients with hematuria: comparison of bladder cancer with other causes.

Goossens-Laan CA, Kil PJ, Ruud Bosch JL, De Vries J.

Qual Life Res. 2013 Mar;22(2):309-15. doi: 10.1007/s11136-012-0163-1. Epub 2012 Mar 30.

PMID:
22461137
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ.

Eur J Cancer. 2012 Aug;48(12):1809-15. doi: 10.1016/j.ejca.2012.02.002. Epub 2012 Mar 7.

PMID:
22406050
[PubMed - indexed for MEDLINE]
7.

Urologists' and GPs' knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands.

Cremers R, van Asperen C, Kil P, Vasen H, Wiersma T, van Oort I, Kiemeney L.

Fam Cancer. 2012 Jun;11(2):195-200. doi: 10.1007/s10689-011-9500-8.

PMID:
22160565
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.

van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I, Steyerberg EW.

BJU Int. 2012 Jul;110(2):180-7. doi: 10.1111/j.1464-410X.2011.10679.x. Epub 2011 Nov 23.

PMID:
22112199
[PubMed - indexed for MEDLINE]
9.

Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume.

Goossens-Laan CA, Visser O, Hulshof MC, Wouters MW, Bosch JL, Coebergh JW, Kil PJ.

BJU Int. 2012 Jul;110(2):226-32. doi: 10.1111/j.1464-410X.2011.10694.x. Epub 2011 Nov 1.

PMID:
22044615
[PubMed - indexed for MEDLINE]
10.

Compliance with biopsy recommendations of a prostate cancer risk calculator.

van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Steyerberg EW, Korfage I.

BJU Int. 2012 May;109(10):1480-8. doi: 10.1111/j.1464-410X.2011.10611.x. Epub 2011 Sep 20.

PMID:
21933335
[PubMed - indexed for MEDLINE]
11.

Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion.

Tombal B, Ameye F, de la Taille A, de Reijke T, Gontero P, Haese A, Kil P, Perrin P, Remzi M, Schröder J, Speakman M, Volpe A, Meesen B, Stoevelaar H.

World J Urol. 2012 Apr;30(2):251-6. doi: 10.1007/s00345-011-0721-0. Epub 2011 Jul 1.

PMID:
21720862
[PubMed - indexed for MEDLINE]
12.

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A.

J Urol. 2011 Jun;185(6):2119-25. doi: 10.1016/j.juro.2011.01.075. Epub 2011 Apr 15.

PMID:
21496856
[PubMed - indexed for MEDLINE]
13.

Polymerase chain reaction-restriction fragment length polymorphism of the rpoB gene for identification of Mycobacterium avium subsp. paratuberculosis and differentiation of Mycobacterium avium subspecies.

Whang J, Lee BS, Choi GE, Cho SN, Kil PY, Collins MT, Shin SJ.

Diagn Microbiol Infect Dis. 2011 May;70(1):65-71. doi: 10.1016/j.diagmicrobio.2011.01.014. Epub 2011 Mar 22.

PMID:
21429694
[PubMed - indexed for MEDLINE]
14.

A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate.

Goossens-Laan CA, Gooiker GA, van Gijn W, Post PN, Bosch JL, Kil PJ, Wouters MW.

Eur Urol. 2011 May;59(5):775-83. doi: 10.1016/j.eururo.2011.01.037. Epub 2011 Feb 1. Review.

PMID:
21310525
[PubMed - indexed for MEDLINE]
15.

Quality of care indicators for muscle-invasive bladder cancer.

Goossens-Laan CA, Kil PJ, Roukema JA, Bosch JL, De Vries J.

Urol Int. 2011;86(1):11-8. doi: 10.1159/000319369. Epub 2010 Oct 7.

PMID:
20926847
[PubMed - indexed for MEDLINE]
16.

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun FK.

Eur Urol. 2010 Nov;58(5):727-32. doi: 10.1016/j.eururo.2010.06.038. Epub 2010 Jul 3.

PMID:
20619529
[PubMed - indexed for MEDLINE]
17.

Variations in treatment policies and outcome for bladder cancer in the Netherlands.

Goossens-Laan CA, Visser O, Wouters MW, Jansen-Landheer ML, Coebergh JW, van de Velde CJ, Hulshof MC, Kil PJ.

Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S100-7. doi: 10.1016/j.ejso.2010.06.003. Epub 2010 Jul 2.

PMID:
20598491
[PubMed - indexed for MEDLINE]
18.

Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006.

Cremers RG, Karim-Kos HE, Houterman S, Verhoeven RH, Schröder FH, van der Kwast TH, Kil PJ, Coebergh JW, Kiemeney LA.

Eur J Cancer. 2010 Jul;46(11):2077-87. doi: 10.1016/j.ejca.2010.03.040. Epub 2010 May 12.

PMID:
20471247
[PubMed - indexed for MEDLINE]
19.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

PMID:
20357281
[PubMed - indexed for MEDLINE]
Free Article
20.

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.

Mattiasson A, Masala A, Morton R, Bolodeoku J; SOLAR Study Group.

BJU Int. 2010 Apr;105(8):1126-35. doi: 10.1111/j.1464-410X.2009.08910.x. Epub 2009 Oct 10.

PMID:
19818077
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk